Added VALUE of an ancillary study on ambulatory blood pressure monitoring

Journal of Hypertension

Volumn 25, Issue 3, 2007, Pages 513-515

  Staessen, Jan A ^a,d   Hansen, Tine Willum ^b   Birkenhäger, Willem H ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Research for Prevention and Health   (Denmark)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VALSARTAN;

BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; EDITORIAL; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 33846826990     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32804955d6     Document Type: Editorial

References (21)

1. Mann J, Julius S, for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7:176-183.
2. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet 2004; 363:2022-2031.
3. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE Trial: long-term blood pressure trends in 13 449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16:544-548.
4. Lederballe-Pedersen O, Mancia G, Pickering T, Hoegholm A, Julius S, Kjeldsen SE, et al. Ambulatory blood pressure monitoring after one year on valsartan based treatment. A value substudy. J Hypertens 2007; 25:707-712.
5. Yusuf S, Collins R, Peto R. Why do we need large, simple randomized trials? Stat Med 1984; 3:409-422.
6. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28:385-407.
7. Staessen JA, Thijs L, Byttebier G, Clement D, O'Brien ET, Palatini P, et al. Determining the trough-to-peak ratio in parallel-group trials. Hypertension 1997; 29:659-667.
8. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100:354-360.
9. Wagstaff AJ. Valsartan/hydrochlorothiazide. Drugs 2006; 66:1881-1901.
10. Burnier M, Brunner HR. Angiotensin II receptor antagonists. The Lancet 2000; 355:637-645.
11. Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992; 80 (Suppl 1):31-36.
12. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992; 22:22-31.
13. Hernández-Hernández R, Armas de Hernández MJ, Armas-Padilla MC, Carvajal AR, Guerrero-Pajuelo J. The effect of missing dose of enalapril on ambulatory blood pressure. Blood Press Monit 1996; 1:121-126.
14. Sasaguri M, Matsumoto N, Noda K, Koga M, Kinoshita A, Ideishi M, et al. Amlodipine lowers blood pressure without increasing sympathetic activity or activating the renin-angiotensin system in patients with essential hypertension. Eur J Clin Pharmacol 1997; 53:197-201.
15. Hamada T, Watanabe M, Kaneda T, Ohtahara A, Kinugawa T, Hisatome I, et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16:111-118.
16. de Champlain J, Karas M, Nguyen P, Cartier P, Wistaff R, Toal CB, et al. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16:1357-1369.
17. Grassi G, Spaziani D, Seravalle G, Bertinieri G, Dell'Oro R, Cuspidi C, et al. Effects of amlodipine on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Hypertension 1999; 33:671-675.
18. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin Outcome Study. Hypertension 2005; 46:156-161.
19. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348:2407-2415.
20. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease change with aging? The Framingham Heart Study. Circulation 2001; 103:1245-1249.
21. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282:539-546.